Targeted Treatment With Combination Chemotherapy Treated First Advanced Lung Adenocarcinoma Patients With EGFR Exon 21mutation:A Retrospective Study

ObjectiveTo explore the efficacy of targeted therapy combined with chemotherapy or targeted therapy alone in newly treated patients with advanced lung adenocarcinoma with EGFR 21 exon point mutation.MethodsA retrospective analysis was performed on patients diagnosed with advanced non-small cell lung cancer(NSCLC)and EGFR from January 2016 to June 2020 in a third class A hospital in Nanchang city,Jiangxi Province.There were 104 patients with exon 21 point mutation,including 45 patients in the targeted combination chemotherapy group and 59 patients in the targeted therapy group.PFS of patients in the targeted combination chemotherapy group and the targeted therapy group were compared,and objective response rate,disease control rate and safety of patients brought by the two treatment plans were analyzed by subgroup.ResultsPFS in chemotherapy combined with targeted therapy(median 13.9 months;95% CI:12.5 to 15.3 months)outperformed PFS in targeted therapy alone(median10.2 months;95% CI:9.6-10.8 months),and were statistically significant(P<0.001).After 4 cycles of treatment,the disease control rate and objective response rate in 2groups were insignificant(P > 0.05).In terms of safety,compared with the single drug group,the adverse events caused by chemotherapy combined with targeted therapy were more common,but the grade of adverse reactions could be reduced after active treatment.ConclusionThe existing EGFR 21 exons mutations at the beginning of the patients with advanced lung adenocarcinoma,targeted therapy in combination with chemotherapy is simply bring a longer survival benefit and good security.